Register Financial Advisors LLC reduced its holdings in shares of MiMedx Group, Inc. (NASDAQ:MDXG – Free Report) by 10.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 33,800 shares of the company’s stock after selling 4,000 shares during the quarter. Register Financial Advisors LLC’s holdings in MiMedx Group were worth $260,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds also recently modified their holdings of the business. Charles Schwab Investment Management Inc. lifted its position in shares of MiMedx Group by 8.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,076,509 shares of the company’s stock valued at $7,848,000 after acquiring an additional 85,792 shares in the last quarter. Citigroup Inc. lifted its holdings in MiMedx Group by 30.2% in the 3rd quarter. Citigroup Inc. now owns 94,646 shares of the company’s stock valued at $690,000 after purchasing an additional 21,976 shares in the last quarter. DekaBank Deutsche Girozentrale purchased a new position in MiMedx Group in the 3rd quarter valued at about $38,000. Algert Global LLC acquired a new stake in shares of MiMedx Group during the 3rd quarter worth about $570,000. Finally, Profund Advisors LLC grew its holdings in shares of MiMedx Group by 50.5% during the third quarter. Profund Advisors LLC now owns 39,309 shares of the company’s stock worth $287,000 after buying an additional 13,187 shares in the last quarter. Hedge funds and other institutional investors own 79.15% of the company’s stock.
MiMedx Group Trading Up 2.5 %
MDXG stock opened at $6.93 on Friday. The company has a quick ratio of 2.71, a current ratio of 3.29 and a debt-to-equity ratio of 0.12. The company has a market cap of $1.02 billion, a price-to-earnings ratio of 15.75 and a beta of 1.91. The business has a fifty day simple moving average of $7.15 and a 200-day simple moving average of $7.67. MiMedx Group, Inc. has a 52 week low of $5.57 and a 52 week high of $9.27.
Analysts Set New Price Targets
Several equities analysts recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $11.00 price objective on shares of MiMedx Group in a research note on Wednesday, May 1st. StockNews.com upgraded MiMedx Group from a “buy” rating to a “strong-buy” rating in a report on Monday, June 3rd. Mizuho lifted their price objective on MiMedx Group from $13.00 to $14.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Finally, Lake Street Capital started coverage on MiMedx Group in a research report on Thursday, March 7th. They set a “buy” rating and a $12.00 target price on the stock. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $12.25.
Read Our Latest Report on MDXG
About MiMedx Group
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
Featured Articles
- Five stocks we like better than MiMedx Group
- What are earnings reports?
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- How to invest in marijuana stocks in 7 stepsĀ
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- 3 Best Fintech Stocks for a Portfolio Boost
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.